Top Penny Stocks Worth Keeping an Eye On: $PRSNF /
Post# of 24967
(Total Views: 96)
Posted On: 08/14/2023 10:35:48 AM
Top Penny Stocks Worth Keeping an Eye On: $PRSNF / $PRSN.V, $NWBO, $AABB, $CYDY
https://www.marketscreener.com/quote/stock/PE...-44606131/
There are numerous companies that are currently accomplishing sterling work in their respective fields and ought to have the attention of investors. Here is a closer look at four such companies:
Personas Social Incorporated (TSX.V: PRSN) (OTCQB: PRSNF) is involved in providing live videoconferencing technology, social media products, live streaming, and other services targeted at businesses and consumers. It is mainly focused on mobile products.
The company also offers commerce-oriented social media products that provide a monetizable experience to all users, businesses, and other consumers. Personas Social accomplishes this by providing products with enterprise-grade e-commerce infrastructure. Some of the features of those products include multi-lingual, multi-currency, and turnkey mobile commerce suites for the users.
The launch of Threads by Meta has made the social media industry the point of focus among many investors once again, and Personas Social issued an update this year about its work on its own social media platform. The company had announced in February 2023 that it was going to re-launch the social media platform named Keek at some point in the spring of 2023. The new avatar of the platform would be called Keek Social.
The platform allows users to share short or long-form videos while connecting with other users on Keek Social. Kim Kardashian West, the American celebrity, originally launched Keek. She had named it after her own nickname, Keek. However, her team abandoned the entire project. Personas Social moved in to revive and redevelop the project.
The platform returned after a hiatus of six years, but this time the focus was on simplicity, strong creator tools, and fun. The platform provides an intuitive and seamless experience to the users so that it is possible for them to share their lives with others on the platform. In July, the company came up with an update about the relaunch of the platform. It announced that the first phase of the four-phase relaunch had taken place on June 28.
Personas Social announced at the time that it would get into the marketing phase of the relaunch in September 2023. The company went for a four-phase re-launch in order to maximize user acquisition and retention. Both of those aspects are pillars of marketing efforts. It was also noted that the marketing efforts would reach as many as 100 million people.
On July 28, the company announced that the iOS version of Keek had been made available for download from the Apple App Store. Personas Social announced at the time that the iOS version had been approved by the Apple App Store. In fact, both the iOS and Android versions of the app were available at the time. In the same news release, Personas Social announced that it would launch its marketing campaign in the coming weeks.
Some of the aspects of the marketing efforts would include marketing to more than a million social media followers, influencer promotions, celebrity promotions, and marketing to 70 million legacy Keek users. A specific focus would be on marketing the platform in India and jurisdictions in the United States where TikTok is banned or would be banned imminently.
Northwest Biotherapeutics (OTC: NWBO) is a biotech company that is involved in the development of customized immunotherapy products. The products are meant to treat cancer with better effectiveness than existing treatments in North America and Europe. The products do not contain the sort of toxicities that are associated with treatments like chemotherapy.
Currently, the company is involved in the development of DCVax-customized immune therapies meant for treating solid cancer tumors. On March 20, the company made a joint announcement with the United Kingdom-based contract development and manufacturing organization (CDMO) leader Advent BioServices Inc.
The announcement referred to the fact that it had been issued an MIA license by the Medicines and Healthcare Products Regulatory Agency (MHRA). Thanks to the license, the company would be able to commercially manufacture cell therapy-related products at its GMP facility located in Sawston, the United Kingdom.
Asia Broadband Inc. (OTC: AABB) The resource-focused company Asia Broadband Inc. is involved in the supply, sale, and production of base and precious metals. It mainly sells its metals in Asian markets. On August 3, the company announced that it had started the preparations to install the processing plant machinery and laboratory analysis equipment for its new plant located in Etzaltan, Mexico.
The delivery of the equipment and installation arrangements followed soon after its representatives had completed facility tours and meetings with mining processing manufacturers in China. The companies with which the company had meetings were Zhengzhou-based Mecru Heavy Industry Technology Co., Ltd. and Liming Heavy Industry Science & Technology Co., Ltd. During those meetings, Asia Broadband representatives secured and verified the shipments as well as deliveries of the processing equipment for its facility in Mexico. The company's management and technical advisors are working on the acceleration of the facility's development. They have set the completion timeline for full operations for the third quarter of 2023.
CytoDyn Inc. (OTC: CYDY): The clinical-stage biotech firm CytoDyn Inc. is involved in the commercialization and development of leronlimab. The product is an investigational humanized IgG4 monoclonal antibody (mAb). The company designed it to bind it to the protein on the surface of certain immune system cells named C-C chemokine receptor type 5 so as to help with the prevention of a number of diseases.
On July 11, the company announced that it had submitted a supplemental Statement of Claim and made a formal request for a hearing date to move forward its litigation against Amarex Clinical Research LLC. Amarex was the former contract research organization for the company. Additionally, CytoDyn also announced that, following his medical leave of absence, Dr. Cyrus Arman returned to the company in the new role of Senior Vice President of Business Operations.
https://www.marketscreener.com/quote/stock/PE...-44606131/
There are numerous companies that are currently accomplishing sterling work in their respective fields and ought to have the attention of investors. Here is a closer look at four such companies:
Personas Social Incorporated (TSX.V: PRSN) (OTCQB: PRSNF) is involved in providing live videoconferencing technology, social media products, live streaming, and other services targeted at businesses and consumers. It is mainly focused on mobile products.
The company also offers commerce-oriented social media products that provide a monetizable experience to all users, businesses, and other consumers. Personas Social accomplishes this by providing products with enterprise-grade e-commerce infrastructure. Some of the features of those products include multi-lingual, multi-currency, and turnkey mobile commerce suites for the users.
The launch of Threads by Meta has made the social media industry the point of focus among many investors once again, and Personas Social issued an update this year about its work on its own social media platform. The company had announced in February 2023 that it was going to re-launch the social media platform named Keek at some point in the spring of 2023. The new avatar of the platform would be called Keek Social.
The platform allows users to share short or long-form videos while connecting with other users on Keek Social. Kim Kardashian West, the American celebrity, originally launched Keek. She had named it after her own nickname, Keek. However, her team abandoned the entire project. Personas Social moved in to revive and redevelop the project.
The platform returned after a hiatus of six years, but this time the focus was on simplicity, strong creator tools, and fun. The platform provides an intuitive and seamless experience to the users so that it is possible for them to share their lives with others on the platform. In July, the company came up with an update about the relaunch of the platform. It announced that the first phase of the four-phase relaunch had taken place on June 28.
Personas Social announced at the time that it would get into the marketing phase of the relaunch in September 2023. The company went for a four-phase re-launch in order to maximize user acquisition and retention. Both of those aspects are pillars of marketing efforts. It was also noted that the marketing efforts would reach as many as 100 million people.
On July 28, the company announced that the iOS version of Keek had been made available for download from the Apple App Store. Personas Social announced at the time that the iOS version had been approved by the Apple App Store. In fact, both the iOS and Android versions of the app were available at the time. In the same news release, Personas Social announced that it would launch its marketing campaign in the coming weeks.
Some of the aspects of the marketing efforts would include marketing to more than a million social media followers, influencer promotions, celebrity promotions, and marketing to 70 million legacy Keek users. A specific focus would be on marketing the platform in India and jurisdictions in the United States where TikTok is banned or would be banned imminently.
Northwest Biotherapeutics (OTC: NWBO) is a biotech company that is involved in the development of customized immunotherapy products. The products are meant to treat cancer with better effectiveness than existing treatments in North America and Europe. The products do not contain the sort of toxicities that are associated with treatments like chemotherapy.
Currently, the company is involved in the development of DCVax-customized immune therapies meant for treating solid cancer tumors. On March 20, the company made a joint announcement with the United Kingdom-based contract development and manufacturing organization (CDMO) leader Advent BioServices Inc.
The announcement referred to the fact that it had been issued an MIA license by the Medicines and Healthcare Products Regulatory Agency (MHRA). Thanks to the license, the company would be able to commercially manufacture cell therapy-related products at its GMP facility located in Sawston, the United Kingdom.
Asia Broadband Inc. (OTC: AABB) The resource-focused company Asia Broadband Inc. is involved in the supply, sale, and production of base and precious metals. It mainly sells its metals in Asian markets. On August 3, the company announced that it had started the preparations to install the processing plant machinery and laboratory analysis equipment for its new plant located in Etzaltan, Mexico.
The delivery of the equipment and installation arrangements followed soon after its representatives had completed facility tours and meetings with mining processing manufacturers in China. The companies with which the company had meetings were Zhengzhou-based Mecru Heavy Industry Technology Co., Ltd. and Liming Heavy Industry Science & Technology Co., Ltd. During those meetings, Asia Broadband representatives secured and verified the shipments as well as deliveries of the processing equipment for its facility in Mexico. The company's management and technical advisors are working on the acceleration of the facility's development. They have set the completion timeline for full operations for the third quarter of 2023.
CytoDyn Inc. (OTC: CYDY): The clinical-stage biotech firm CytoDyn Inc. is involved in the commercialization and development of leronlimab. The product is an investigational humanized IgG4 monoclonal antibody (mAb). The company designed it to bind it to the protein on the surface of certain immune system cells named C-C chemokine receptor type 5 so as to help with the prevention of a number of diseases.
On July 11, the company announced that it had submitted a supplemental Statement of Claim and made a formal request for a hearing date to move forward its litigation against Amarex Clinical Research LLC. Amarex was the former contract research organization for the company. Additionally, CytoDyn also announced that, following his medical leave of absence, Dr. Cyrus Arman returned to the company in the new role of Senior Vice President of Business Operations.
(0)
(0)Scroll down for more posts ▼